Juvenile dermatomyositis (JDM) is a rare autoimmune disease in which the immune system attacks the small blood vessels that supply muscles and skin, causing progressive muscle weakness and a distinctive rash that often appears on the eyelids, knuckles, and face. It is the most common form of childhood-onset myositis, though still rare overall, typically diagnosed between ages 2 and 16. Modern treatment has greatly improved outcomes, but children with JDM often face years of immune-suppressing medication, visible skin changes, and unpredictable flares of weakness and fatigue. Research increasingly shows that depression and anxiety are a meaningful part of this experience — shaped not only by the visible and unpredictable nature of the illness, but also, surprisingly, by inflammation itself at a biological level.
How Common Is Depression and Anxiety in Juvenile Dermatomyositis?
A 2026 feasibility study of a group-based narrative medicine program for children with JDM and juvenile idiopathic arthritis (JIA) cites anxiety and depression rates ranging from 15% to 65% in these conditions, well above rates seen in healthy children. The study itself recruited 21 participants ages 6 to 21 (12 with JDM, 9 with JIA) for six narrative medicine sessions over three months, in which children reflected on their medical experiences in a group setting. Across the full group, standard depression and anxiety questionnaires showed no statistically significant change from before to after the program. But among the subset of participants who started with elevated anxiety or depression scores, there was a trend toward improved anxiety (p = 0.057, just short of significance) though not depression (p = 0.171). Ninety-one percent of participants attended at least four of the six sessions, showing that this kind of program is feasible for children managing a chronic illness, even if its emotional benefits remain uncertain and likely modest.
Everyday Struggles
- Managing a visible rash during childhood and adolescence. JDM often causes a distinctive rash on the face, eyelids, and knuckles, and visible skin changes during the school years can bring unwanted attention, questions, or self-consciousness at an age when fitting in matters enormously.
- Living with unpredictable flares of muscle weakness. Because disease activity can wax and wane, children may have good stretches followed by sudden flares that make stairs, writing, or simply getting dressed newly difficult, which can be both physically frustrating and emotionally destabilizing.
- Enduring years of immune-suppressing treatment. Many children remain on medications like corticosteroids and other immunosuppressants for years, which can affect growth, appearance, and energy levels, and often means frequent clinic visits and lab draws well into adolescence.
- Carrying uncertainty about what the illness will do next. Not knowing whether a flare, a new symptom, or a long remission is coming next is itself a documented source of distress, separate from how severe the disease happens to be at any given moment.
- Watching the whole family reorganize around the diagnosis. Because JDM is usually diagnosed in early-to-mid childhood, parents and siblings often take on years of caregiving, appointment-scheduling, and medication routines, and the emotional weight of the illness is rarely confined to the child alone.
Illness Uncertainty Predicts Distress — But Resilience Alone Doesn't Fix It
A 2026 study drew on the UK-wide Juvenile Dermatomyositis Cohort and Biomarker Study, gathering detailed questionnaire data from 123 children and young people with JDM to test a model of how illness uncertainty, perceived burden, and resilience factors relate to anxiety and depression. Using structural equation modeling, the researchers found that how strongly a child perceives their illness as uncertain and burdensome was a powerful predictor of emotional distress (a standardized path coefficient of 0.93, among the strongest associations the model could show). Resilience factors, including a child's sense of having found some benefit in their experience with illness, did not significantly improve mental health outcomes in the same model. The authors concluded that directly addressing how uncertain and burdensome an illness feels to a child may matter more for protecting mental health than trying to cultivate resilience or positive reframing alone.
A Biological Link Between Inflammation and Mood
A 2026 study compared blood samples from 38 children with JDM, 12 with JIA, and 21 healthy children, measuring how the amino acid tryptophan is broken down in the body. In children with JDM, tryptophan was increasingly shunted down an inflammation-linked pathway that produces kynurenine and related byproducts, while serotonin — made from the same starting material — was correspondingly lower. Lower serotonin was linked to greater psychosocial impairment (r = -0.74), and one kynurenine byproduct, kynurenic acid, was linked to lower depression scores (r = -0.53) — a finding the researchers describe as a possible protective, rather than harmful, role for this particular byproduct, in contrast to how the same pathway often behaves in adult depression research. In laboratory experiments, the researchers also traced this shift back to type I interferon signaling, a hallmark of JDM's underlying inflammation, and found it could be blocked by two existing anti-inflammatory medications — raising the possibility that treating the underlying inflammation more effectively could someday help mood alongside muscle and skin symptoms.
Practical Tips
- Ask your child's rheumatology team about mental health check-ins, not just disease activity. Because emotional wellbeing in JDM is tied to biological, psychological, and social factors all at once, a care team that only tracks muscle strength and skin findings may miss a meaningful part of the picture.
- Name illness uncertainty out loud, rather than only focusing on current symptoms. Research suggests that how uncertain and burdensome an illness feels can matter more for a child's mental health than how active the disease is right now, so it can help to talk openly about not-knowing as its own real source of stress.
- Treat resilience-building as a helpful addition, not a replacement for direct support. Finding meaning or benefit in a difficult experience is a reasonable goal, but research suggests it is not enough on its own to protect against anxiety and depression in JDM, so it works best alongside real emotional and practical support.
- Consider a structured group program, but keep expectations modest. Group-based approaches like narrative medicine show that children with JDM and JIA can engage consistently with this kind of support, even though measurable mood improvements may be small or limited to those starting with more symptoms.
- Keep an eye on skin-related self-consciousness as its own issue. Because JDM's rash is visible and can affect how children feel seen by peers, it is worth checking in specifically about body image and social comfort, not only about physical symptoms or disease activity.